CoLucid Pharmaceuticals, Inc.
CLCD
CLCD was delisted on the 28th of February, 2017.
1 hedge funds and large institutions have $55K invested in CoLucid Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 71 closing their positions.
99% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 71
99% less funds holding
Funds holding: 76 → 1 (-75)
100% less capital invested
Capital invested by funds: $503M → $55K (-$503M)
100% less funds holding in top 10
Funds holding in top 10: 6 → 0 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FPF
FNY Partners Fund
New York
|
+$51.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$115M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$84.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$48M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$25.6M |
| 5 |
PA
Perceptive Advisors
New York
|
-$23.3M |
CLCD Hedge Fund Activity: Q1 2017 in Review
1 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q1 2017, worth a combined $55K — down 100% from $503M a quarter earlier.
Sellers outnumbered buyers: 71 funds closed out of CLCD and 1 opened new positions — a net loss of 70 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was FNY Partners Fund, opening a new position worth an estimated $51.9K. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $115M sold.
- 1 institutional investor held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q1 2017, down from 76 in Q4 2016.
- Funds reported $55K of CoLucid Pharmaceuticals, Inc. stock for Q1 2017, down 100% quarter-over-quarter.
- 1 fund opened new CoLucid Pharmaceuticals, Inc. positions in Q1 2017 and 71 closed out, a net change of -70 holders.
- The largest CoLucid Pharmaceuticals, Inc. buyer in Q1 2017 was FNY Partners Fund, an estimated $51.9K added.
- The largest CoLucid Pharmaceuticals, Inc. seller in Q1 2017 was Novo Holdings A/S, an estimated $115M sold.
Based on aggregated 13F filings for Q1 2017.